ADBE vs PFE: Which Is the Better Buy?

Side-by-side comparison of Adobe Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-16.
Adobe Inc. · Technology
$248.16
+163.1% upside to fair value
High Conviction Grade B
VS
Pfizer Inc. · Healthcare
$26.91
+30.1% upside to fair value
Med Conviction Grade B+
QuantHub Verdict
ADBE has more upside to fair value (+163.1%). PFE trades at a lower forward P/E (9.5x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric ADBE PFE
Current Price $248.16 $26.91
Fair Value Estimate $653.00 $35.00
Upside to Fair Value +163.1% +30.1%
Market Cap $101.2B $153.0B
Forward P/E 14.1x 9.5x
EV / EBITDA 13.8x
Price / Sales 4.1x 2.4x
Price / FCF 9.8x 16.8x
Revenue Growth YoY +3.3% -1.6%
Gross Margin 89.1% 70.3%
Operating Margin 36.6% 24.7%
Return on Equity 62.3% 9.0%
Dividend Yield 6.4%
FCF Yield 10.2% 5.9%
Analyst Consensus Hold Hold
Investment Thesis
ADBE — Adobe Inc.
Adobe Inc. develops industry-leading creative software, digital experience platforms, and publishing tools, powering digital content creation and marketing for professionals worldwide. The business excels with high gross margins above 89%, a sticky subscription model driving recurring revenue over $17B ARR, and dominant moats in digital media, though it faces intensifying AI competition and slowi…
PFE — Pfizer Inc.
Pfizer remains the world's largest traditional pharmaceutical company by non-COVID revenue, generating $62.6B in 2025 sales across oncology, cardiovascular, immunology, and vaccines. The stock trades at a P/S of 2.44x, still well below the 5-year median of 3.10x, driven by post-COVID revenue normalization, a $17-18B patent cliff spanning 2026-2028, and $61.6B in acquisition-related debt from Seag…
Accumulation Zones
Metric ADBE PFE
Zone Low $490.00 $25.00
Zone High $555.00 $29.00
In Buy Zone? Yes Yes
← ADBE Research    PFE Research →    All Research